Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name	Nivolumab and relatlimab-rmbw
Synonyms
Therapy Description	Opdualag (nivolumab and relatlimab-rmbw) is a fixed-dose combination of Relatlimab (BMS-986016) and Opdivo (nivolumab), which may lead to enhanced anti-tumor immune response (PMID: 34986285). Opdualag (nivolumab and relatlimab-rmbw) is FDA approved for use in adult and pediatric patients of 12 years or older with unresectable or metastatic melanoma (FDA.gov).

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Nivolumab and relatlimab-rmbw	Opdualag	BMS-986213	LAG3 Antibody 18 PD-L1/PD-1 antibody 129	Opdualag (nivolumab and relatlimab-rmbw) is a fixed-dose combination of Relatlimab (BMS-986016) and Opdivo (nivolumab), which may lead to enhanced anti-tumor immune response (PMID: 34986285). Opdualag (nivolumab and relatlimab-rmbw) is FDA approved for use in adult and pediatric patients of 12 years or older with unresectable or metastatic melanoma (FDA.gov).

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 0 to 0 of 0 entries

Showing 0 to 0 of 0 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 12 of 12 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT04953104	Phase II	Nivolumab and relatlimab-rmbw	ARID1A and/or KDM6A Mutation and CXCL13 Expression	Active, not recruiting	USA	0
NCT05328908	Phase III	Regorafenib + Trifluridine-tipiracil hydrochloride Nivolumab and relatlimab-rmbw	A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123)	Active, not recruiting	USA \| SWE \| POL \| NLD \| ITA \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BEL \| AUT \| AUS \| ARG	7
NCT06101134	Phase II	BMS-986298 Nivolumab + Relatlimab + rHuPH20 Nivolumab and relatlimab-rmbw Nivolumab	A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations	Active, not recruiting	USA \| ITA \| GRC \| ESP	1
NCT06624475	Phase II	Nivolumab and relatlimab-rmbw Nivolumab	Neoadjuvant Opdualag Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma	Not yet recruiting	USA	0
NCT05418972	Phase II	Nivolumab and relatlimab-rmbw	A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II)	Recruiting	AUS	0
NCT05704647	Phase II	Nivolumab and relatlimab-rmbw	Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases	Recruiting	USA	0
NCT06264180	Phase III	Nab-paclitaxel Nivolumab + RP1 Paclitaxel Nivolumab and relatlimab-rmbw Nivolumab Dacarbazine Pembrolizumab Temozolomide	VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)	Recruiting	USA	0
NCT06288191	Phase II	Nivolumab and relatlimab-rmbw	Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma	Recruiting	AUS	0
NCT06295159	Phase I	Nivolumab Nivolumab and relatlimab-rmbw Ipilimumab + Nivolumab	Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma	Recruiting	USA	0
NCT06319196	Phase II	Nivolumab Nivolumab and relatlimab-rmbw	Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma (ClearMe)	Recruiting	CAN	0
NCT06715241	Phase II	Nivolumab and relatlimab-rmbw Nivolumab	A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II of RELATLIMAB and NIVOLUMAB VS NIVOLUMAB ALONE in LOCALLY ADVANCED CERVICAL CANCERS (COLIBRI-2)	Recruiting	FRA	0
NCT06743126	Phase III	Pembrolizumab Temozolomide Carboplatin + Paclitaxel Lifileucel Dacarbazine Nivolumab Paclitaxel Nivolumab and relatlimab-rmbw Nab-paclitaxel Ipilimumab IMA-203	SUPRAME-ACTengine IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (SUPRAME)	Recruiting	USA \| DEU	0

Showing 1 to 12 of 12 entries

Filter rows:

Additional content available in CKB BOOST